Skip to main content

Table 1 Baseline clinical characteristics of the study population

From: Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy

  Total Group A Group B P-value
Age 61 ± 13 64 ± 12 59 ± 12 0.14
Male 73 (72%) 18 (74%) 55 (71%) 0.63
BPs (mmHg) 130 ± 19 137 ± 23 128 ± 17 0.04
BPd (mmHg) 77 ± 10 79 ± 10 76 ± 10 0.14
Height (m) 1.62 ± 0.09 1.60 ± 0.08 1.63 ± 0.09 0.12
Weight (kg) 61.8 ± 11.1 61.9 ± 9.6 61.7 ± 11.8 0.94
BSA (m2 ) 1.67 ± 0.18 1.65 ± 0.16 1.67 ± 0.19 0.75
History of
HT
43 (42%) 16 (67%) 27 (35%) <0.0001
DM 10 (10%) 3 (13%) 7 (9%) 0.37
HL 49 (48%) 12 (50%) 37 (47%) 0.67
PAF 23 (23%) 13 (54%) 10 (13%) <0.0001
Medications
Aspirin
15 (15%) 8 (33%) 7 (9%) <0.0001
Warfarin 4 (17%) 4 (17%) 0 <0.001
Calcium ant. 41 (40%) 11 (46%) 30 (38%) 0.25
Beta-blockers 44 (43%) 11 (46%) 33 (42%) 0.57
Diuretics 6 (6%) 3 (13%) 3 (4%) 0.02
ACE inhibitor 19 (19%) 8 (33%) 11 (14%) 0.002
  1. BPs, systolic blood pressure; BPd, diastolic blood pressure
  2. BSA, body surface area; PAF, paroxysmal atrial fibrillation